All posts by: Michael Zand

About Michael Zand

Patients Now Have the Option to Undergo Immunotherapy Less Frequently – Curetoday.com

Continue reading

2018-03-06 NEWS

Patients Now Have the Option to Undergo Immunotherapy Less Frequently
Curetoday.com
The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications. PUBLISHED March 06, 2018. The Food and Drug

and more »

Continue reading

2018-03-06 NEWS

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting …
GlobeNewswire (press release)
BEVERLY HILLS, CA, March 06, 2018 (GLOBE NEWSWIRE) — Rich Pharmaceuticals, Inc. (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical

and more »

Continue reading

2018-03-06 NEWS

Study: Adult human immune cells have stem cell-like function that stimulates healing
Medical Xpress
“It’s interesting that immune cells of adult humans possess such plasticity that they may naturally convert into other cell types of the body,” said Sashwati Roy, co-lead author of the study and a professor of general surgery at the Medical Center. The